Scholar Rock Holding (SRRK) Stock Overview
A biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
SRRK Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Scholar Rock Holding Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$28.78 |
| 52 Week High | US$46.98 |
| 52 Week Low | US$22.71 |
| Beta | 0.43 |
| 1 Month Change | -23.19% |
| 3 Month Change | -22.17% |
| 1 Year Change | 4.01% |
| 3 Year Change | 253.56% |
| 5 Year Change | -31.33% |
| Change since IPO | 85.68% |
Recent News & Updates
Recent updates
Scholar Rock Holding: Upcoming Milestone Approaches
Aug 13Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade
Apr 17Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data
Jan 30Scholar Rock: Likely Approval In SMA Plus Obesity Data In 2025 Intrigue, But Price Too High
Dec 24Scholar Rock: SMA Program Strides Forward With Positive Clinical Data
Oct 07Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt?
Aug 13
Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt?
Apr 15Scholar Rock: Solid Data And Good Prospects
Jan 12Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up
Apr 19Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy
Oct 20Jay Backstrom is the new CEO at Scholar Rock
Sep 20Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology
Jul 12Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts
May 21Shareholder Returns
| SRRK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.6% | 0.8% | -0.9% |
| 1Y | 4.0% | 2.6% | 20.1% |
Return vs Industry: SRRK matched the US Biotechs industry which returned 4% over the past year.
Return vs Market: SRRK underperformed the US Market which returned 20.3% over the past year.
Price Volatility
| SRRK volatility | |
|---|---|
| SRRK Average Weekly Movement | 10.3% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SRRK has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SRRK's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 128 | David Hallal | www.scholarrock.com |
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively target the precursor. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
Scholar Rock Holding Corporation Fundamentals Summary
| SRRK fundamental statistics | |
|---|---|
| Market cap | US$2.85b |
| Earnings (TTM) | -US$315.69m |
| Revenue (TTM) | n/a |
Is SRRK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SRRK income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$210.16m |
| Gross Profit | -US$210.16m |
| Other Expenses | US$105.52m |
| Earnings | -US$315.69m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 14, 2025
| Earnings per share (EPS) | -3.28 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 21.3% |
How did SRRK perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/03 12:44 |
| End of Day Share Price | 2025/11/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Scholar Rock Holding Corporation is covered by 22 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Etzer Darout | Barclays |
| Guyn Kim | BMO Capital Markets Equity Research |